Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 3

NCT ID: NCT01510795 Enrolling by invitation - Clinical trials for Kidney Failure, Chronic

Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology

Start date: January 2012
Phase: Phase 4
Study type: Interventional

Chronic allograft nephropathy is one of dominant causes of long term kidney transplant failure. Its main histological determinant is interstitial fibrosis and tubular atrophy. Mechanisms of these changes are multifactorial and are not completely elucidated. Epithelial mesenchymal transition (EMT) might be one of the mechanisms. On molecular level role of renin angiotensin aldosterone system (RAAS) has been recognized. Recently, mineralocorticoid hormone aldosterone has been proposed as a possible direct contributor to the progression of renal injury and fibrosis, beside his well known role as a regulator of extracellular fluid volume and sodium and potassium balance. In this study the investigators will determine the impact of mineralocorticoid receptor antagonist use on progression of chronic scores in transplanted kidney over one year. The investigators hypothesis is that spironolactone use in kidney transplant patients will slow down progression of chronic histological changes- interstitial fibrosis, tubular atrophy and arteriolar hyalinosis.

NCT ID: NCT00852800 Enrolling by invitation - Renal Impairment Clinical Trials

Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study

ALTERNATE
Start date: March 2006
Phase: Phase 2
Study type: Interventional

Spontaneous bacterial peritonitis (SBP) is a common and severe complication of cirrhosis. The most serious complication of SBP is the hepatorenal syndrome (HRS), which occurs in up to 30 percent of patients, with high mortality. Intravenous albumin (1.5 g/kg at diagnosis and 1 g/kg 48 hours later - standard regimen) helps to prevent HRS and improves survival. No information exists on the efficacy of lower doses of albumin. This study was designed to allow direct comparison among different doses of intravenous albumin in patients with SBP - standard (SR) vs dose reduced regimen (DRR) - in order to prevent renal failure and mortality.